Immunome Announces Promotion of Max Rosett to Chief Financial Officer
17 Mai 2024 - 2:00PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the promotion of Max Rosett to Chief
Financial Officer, effective May 9. Mr. Rosett most recently held
the role of Executive Vice President, Operations, in addition to
serving as Immunome’s Interim Chief Financial Officer since January
2024.
“Max has been instrumental in Immunome’s rapid transformation
over the last year, driving execution of major initiatives
including our merger with Morphimmune, our strategic transactions
with Zentalis and Ayala, and two financings totaling over $350
million,” said Clay Siegall, PhD, President and Chief Executive
Officer. “Max’s strategic insight, financial acumen, and
collaborative approach make him the right Chief Financial Officer
for Immunome as we advance the Phase 3 RINGSIDE trial of AL102 in
desmoid tumors, prepare IM-1021 and IM-3050 for IND submission, and
seek to further expand our pipeline.”
“I am honored to take on the role of Chief Financial Officer,
working alongside exceptional colleagues at a dynamic company,”
said Mr. Rosett. “Immunome’s broad pipeline and compelling
technology platforms present many opportunities to develop
differentiated oncology therapies, and I look forward to advancing
our mission of improving the lives of cancer patients.”
Max previously served in roles of increasing responsibility at
Morphimmune, concluding as Acting Chief Operating Officer, and
joined Immunome in October 2023 at the close of Morphimmune’s
merger with Immunome. Prior to Morphimmune, Mr. Rosett was a
Principal at Research Bridge Partners, a life science investment
firm. He has also worked as a software engineer at Google, and he
started his career at the Boston Consulting Group, where he served
clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in
Computer Science from Georgia Institute of Technology and a B.A. in
Mathematics from Yale University.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including small molecules, ADCs, RLTs and immunotherapies.
We believe that pursuing underexplored targets with appropriate
drug modalities leads to transformative therapies. Our proprietary
memory B cell hybridoma technology allows for the rapid screening
and functional characterization of novel antibodies and
targets.
For more information, visit www.immunome.com or follow us on X
(formerly known as Twitter) and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). We use words such as
“advance,” “seek,” “opportunities,” “potential,” “eager,” and
similar expressions to identify these forward-looking statements
that are intended to be covered by the safe-harbor provisions of
the PSLRA. These forward-looking statements include, but are not
limited to, Immunome’s expectation to advance the Phase 3 RINGSIDE
Part B trial of AL102; Immunome’s expectations for submitting INDs
for IM-3050 and IM-1021; Immunome’s plans to advance its pipeline
and develop first-in-class therapies; and other statements
regarding management’s intentions, plans, beliefs, expectations or
forecasts for the future. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. Such forward-looking statements are based on Immunome’s
expectations and involve risks and uncertainties; consequently,
actual results may differ materially from those expressed or
implied in the statements due to a number of factors, including,
but not limited to, the risk that Immunome will not be able to
realize the benefits of its strategic transactions; Immunome’s
ability to grow and successfully execute on its business plan,
including the development and commercialization of its pipeline and
integration of newly acquired assets; changes in the applicable
laws or regulations; the possibility that Immunome may be adversely
affected by other economic, business, and/or competitive factors;
the risk that regulatory approvals for Immunome’s programs and
product candidates are not obtained, are delayed or are subject to
unanticipated conditions; the risk that pre-clinical data may not
be predictive of clinical data; the risk that interim results of a
clinical trial do not necessarily predict final results; potential
delays in the commencement, enrollment and completion of clinical
trials and the reporting of data therefrom; the risk that
Immunome’s product candidates and development candidates fail to
achieve their intended endpoints; the complexity of numerous
regulatory and legal requirements that Immunome needs to comply
with to operate its business; the reliance on Immunome’s
management; the prior experience and successes of the Immunome’s
management team not being indicative of any future success;
uncertainties related to Immunome’s capital requirements and
Immunome’s expected cash runway; the failure to obtain, adequately
protect, maintain or enforce Immunome’s intellectual property
rights; and other risks and uncertainties indicated from time to
time described in Immunome’s Annual Report on Form 10-K for the
year ended December 31, 2023, filed with the SEC on March 26, 2024,
in Immunome’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2024, filed with the SEC on May 14, 2024, and in
Immunome’s other filings with the SEC. Immunome cautions that the
foregoing list of factors is not exclusive and not to place undue
reliance upon any forward-looking statements which speak only as of
the date made. Moreover, Immunome operates in a very competitive
and rapidly changing environment. New risks emerge from time to
time. Except as required by law, Immunome does not undertake any
obligation to update publicly any forward-looking statements for
any reason after the date of this press release to conform these
statements to actual results or to changes in their
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240517911577/en/
Investor Contact Max Rosett Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024